vs
Side-by-side financial comparison of Idexx Laboratories (IDXX) and Medtronic (MDT), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Medtronic is the larger business by last-quarter revenue ($9.0B vs $1.1B, roughly 8.2× Idexx Laboratories). Idexx Laboratories runs the higher net margin — 22.8% vs 15.3%, a 7.4% gap on every dollar of revenue. On growth, Idexx Laboratories posted the faster year-over-year revenue change (14.3% vs 6.6%). Medtronic produced more free cash flow last quarter ($457.0M vs $326.3M). Over the past eight quarters, Idexx Laboratories's revenue compounded faster (6.4% CAGR vs 5.3%).
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
IDXX vs MDT — Head-to-Head
Income Statement — Q4 2025 vs Q2 2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $9.0B |
| Net Profit | $248.2M | $1.4B |
| Gross Margin | 60.3% | 65.8% |
| Operating Margin | 28.9% | 18.8% |
| Net Margin | 22.8% | 15.3% |
| Revenue YoY | 14.3% | 6.6% |
| Net Profit YoY | 14.8% | 8.2% |
| EPS (diluted) | $3.09 | $1.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $1.1B | $9.0B | ||
| Q3 25 | $1.1B | $8.6B | ||
| Q2 25 | $1.1B | $8.9B | ||
| Q1 25 | $998.4M | $8.3B | ||
| Q4 24 | $954.3M | $8.4B | ||
| Q3 24 | $975.5M | $7.9B | ||
| Q2 24 | $1.0B | $8.6B | ||
| Q1 24 | $964.1M | $8.1B |
| Q4 25 | $248.2M | $1.4B | ||
| Q3 25 | $274.6M | $1.0B | ||
| Q2 25 | $294.0M | $1.1B | ||
| Q1 25 | $242.7M | $1.3B | ||
| Q4 24 | $216.1M | $1.3B | ||
| Q3 24 | $232.8M | $1.0B | ||
| Q2 24 | $203.3M | $654.0M | ||
| Q1 24 | $235.6M | $1.3B |
| Q4 25 | 60.3% | 65.8% | ||
| Q3 25 | 61.8% | 65.0% | ||
| Q2 25 | 62.6% | 64.8% | ||
| Q1 25 | 62.4% | 66.5% | ||
| Q4 24 | 59.8% | 64.9% | ||
| Q3 24 | 61.1% | 65.1% | ||
| Q2 24 | 61.7% | 64.5% | ||
| Q1 24 | 61.5% | 65.6% |
| Q4 25 | 28.9% | 18.8% | ||
| Q3 25 | 32.1% | 16.8% | ||
| Q2 25 | 33.6% | 16.1% | ||
| Q1 25 | 31.7% | 19.9% | ||
| Q4 24 | 27.4% | 19.0% | ||
| Q3 24 | 31.2% | 16.1% | ||
| Q2 24 | 26.3% | 12.3% | ||
| Q1 24 | 31.0% | 18.3% |
| Q4 25 | 22.8% | 15.3% | ||
| Q3 25 | 24.8% | 12.1% | ||
| Q2 25 | 26.5% | 11.8% | ||
| Q1 25 | 24.3% | 15.6% | ||
| Q4 24 | 22.7% | 15.1% | ||
| Q3 24 | 23.9% | 13.2% | ||
| Q2 24 | 20.3% | 7.6% | ||
| Q1 24 | 24.4% | 16.3% |
| Q4 25 | $3.09 | $1.07 | ||
| Q3 25 | $3.40 | $0.81 | ||
| Q2 25 | $3.63 | $0.81 | ||
| Q1 25 | $2.96 | $1.01 | ||
| Q4 24 | $2.62 | $0.99 | ||
| Q3 24 | $2.80 | $0.80 | ||
| Q2 24 | $2.44 | $0.50 | ||
| Q1 24 | $2.81 | $0.99 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $180.1M | $8.3B |
| Total DebtLower is stronger | $450.0M | $27.7B |
| Stockholders' EquityBook value | $1.6B | $48.7B |
| Total Assets | $3.4B | $91.3B |
| Debt / EquityLower = less leverage | 0.28× | 0.57× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $180.1M | $8.3B | ||
| Q3 25 | $208.2M | $8.1B | ||
| Q2 25 | $164.6M | $9.0B | ||
| Q1 25 | $164.0M | $7.9B | ||
| Q4 24 | $288.3M | $8.0B | ||
| Q3 24 | $308.6M | $7.8B | ||
| Q2 24 | $401.6M | $8.0B | ||
| Q1 24 | $397.4M | $8.3B |
| Q4 25 | $450.0M | $27.7B | ||
| Q3 25 | — | $26.2B | ||
| Q2 25 | — | $25.6B | ||
| Q1 25 | — | $24.0B | ||
| Q4 24 | $617.8M | $24.6B | ||
| Q3 24 | — | $26.3B | ||
| Q2 24 | — | $23.9B | ||
| Q1 24 | — | $24.2B |
| Q4 25 | $1.6B | $48.7B | ||
| Q3 25 | $1.6B | $47.9B | ||
| Q2 25 | $1.5B | $48.0B | ||
| Q1 25 | $1.4B | $49.4B | ||
| Q4 24 | $1.6B | $48.5B | ||
| Q3 24 | $1.6B | $47.9B | ||
| Q2 24 | $1.6B | $50.2B | ||
| Q1 24 | $1.6B | $51.8B |
| Q4 25 | $3.4B | $91.3B | ||
| Q3 25 | $3.4B | $91.0B | ||
| Q2 25 | $3.3B | $91.7B | ||
| Q1 25 | $3.2B | $90.0B | ||
| Q4 24 | $3.3B | $90.0B | ||
| Q3 24 | $3.4B | $89.7B | ||
| Q2 24 | $3.4B | $90.0B | ||
| Q1 24 | $3.4B | $90.8B |
| Q4 25 | 0.28× | 0.57× | ||
| Q3 25 | — | 0.55× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | 0.39× | 0.51× | ||
| Q3 24 | — | 0.55× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $355.8M | $925.0M |
| Free Cash FlowOCF − Capex | $326.3M | $457.0M |
| FCF MarginFCF / Revenue | 29.9% | 5.1% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 2.7% | 5.2% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 1.43× | 0.67× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $5.2B |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $355.8M | $925.0M | ||
| Q3 25 | $402.3M | $1.1B | ||
| Q2 25 | $185.7M | $2.5B | ||
| Q1 25 | $238.0M | $2.6B | ||
| Q4 24 | $262.0M | $958.0M | ||
| Q3 24 | $220.1M | $986.0M | ||
| Q2 24 | $248.3M | $2.8B | ||
| Q1 24 | $198.6M | $2.5B |
| Q4 25 | $326.3M | $457.0M | ||
| Q3 25 | $371.2M | $584.0M | ||
| Q2 25 | $151.6M | $2.1B | ||
| Q1 25 | $207.9M | $2.1B | ||
| Q4 24 | $232.8M | $554.0M | ||
| Q3 24 | $192.0M | $466.0M | ||
| Q2 24 | $215.0M | $2.4B | ||
| Q1 24 | $168.3M | $2.1B |
| Q4 25 | 29.9% | 5.1% | ||
| Q3 25 | 33.6% | 6.8% | ||
| Q2 25 | 13.7% | 23.2% | ||
| Q1 25 | 20.8% | 25.3% | ||
| Q4 24 | 24.4% | 6.6% | ||
| Q3 24 | 19.7% | 5.9% | ||
| Q2 24 | 21.4% | 27.4% | ||
| Q1 24 | 17.5% | 26.3% |
| Q4 25 | 2.7% | 5.2% | ||
| Q3 25 | 2.8% | 5.9% | ||
| Q2 25 | 3.1% | 5.1% | ||
| Q1 25 | 3.0% | 5.7% | ||
| Q4 24 | 3.1% | 4.8% | ||
| Q3 24 | 2.9% | 6.6% | ||
| Q2 24 | 3.3% | 5.0% | ||
| Q1 24 | 3.1% | 4.3% |
| Q4 25 | 1.43× | 0.67× | ||
| Q3 25 | 1.47× | 1.05× | ||
| Q2 25 | 0.63× | 2.39× | ||
| Q1 25 | 0.98× | 1.99× | ||
| Q4 24 | 1.21× | 0.75× | ||
| Q3 24 | 0.95× | 0.95× | ||
| Q2 24 | 1.22× | 4.25× | ||
| Q1 24 | 0.84× | 1.87× |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
